Obagi Medical Launches ALOHA Program for Real-World Evaluation of New Hyaluronic Acid Filler
Event summary
- Obagi Medical, part of Waldencast plc, launched the ALOHA Program on January 21, 2026 to support the introduction of Obagi® saypha® MagIQ™, its first FDA-approved injectable hyaluronic acid (HA) filler.
- The ALOHA Program is designed to gather real-world data across diverse practice settings, making it the largest real-world evaluation of a newly launched HA injectable.
- Participants will provide structured feedback via standardized surveys from injectors and practice owners to inform post-launch education and wider adoption.
The big picture
Obagi Medical's ALOHA Program represents a strategic shift towards practice-led innovation in the aesthetic skincare market. By leveraging real-world data, the company aims to differentiate its new HA filler in a competitive landscape dominated by established players. The program aligns with Waldencast plc's vision of building a global beauty and wellness platform through high-growth, purpose-driven brands.
What we're watching
- Adoption Pace
- The pace at which Obagi® saypha® MagIQ™ gains market share against established HA fillers.
- Data Utilization
- How effectively the real-world data from the ALOHA Program informs product improvements and marketing strategies.
- Practice Engagement
- Whether the inclusive design of the ALOHA Program can sustain broad industry participation and feedback.
Related topics